Please login to the form below

Not currently logged in
Email:
Password:

Onconova appoints Ajay Bansal as chief financial officer

He joins from Complete Genomics

Ajay Bansal Onconova TherapeuticsAjay Bansal has left Complete Genomics to join cancer specialists Onconova Therapeutics as chief financial officer and president

Bansal (pictured) served as chief financial officer at Complete Genomics since May 2010, having previously held the role of chief financial officer and executive VP of business development at Lexicon Therapeutics.

He joins US-based Onconova as the company prepares to complete enrolment for a phase III study to investigate lead drug candidate rigosertib in patients with myelodysplastic syndromes.

“The potential benefit of rigosertib for the treatment of patients with both solid and haematological malignancies presents a significant opportunity, and I look forward to helping the company meet its objectives for this compound and the rest of the pipeline,” said Bansal.

In addition to his prior roles at Complete Genomics and Lexicon, Bansal has also served as chief financial officer at Nektar Therapuetics and Tercica, later acquired by Ipsen.

8th April 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics